CN110922361B - 一种依托咪酯氧化杂质及其制备方法 - Google Patents
一种依托咪酯氧化杂质及其制备方法 Download PDFInfo
- Publication number
- CN110922361B CN110922361B CN201911151116.4A CN201911151116A CN110922361B CN 110922361 B CN110922361 B CN 110922361B CN 201911151116 A CN201911151116 A CN 201911151116A CN 110922361 B CN110922361 B CN 110922361B
- Authority
- CN
- China
- Prior art keywords
- etomidate
- preparation
- reaction
- acid
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 title claims abstract description 61
- 229960001690 etomidate Drugs 0.000 title claims abstract description 61
- 239000012535 impurity Substances 0.000 title claims abstract description 34
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 29
- 230000003647 oxidation Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims abstract description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 230000001590 oxidative effect Effects 0.000 claims abstract description 13
- 239000007800 oxidant agent Substances 0.000 claims abstract description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000004440 column chromatography Methods 0.000 claims abstract description 8
- 238000003908 quality control method Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000741 silica gel Substances 0.000 claims description 21
- 229910002027 silica gel Inorganic materials 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 11
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000010791 quenching Methods 0.000 claims description 5
- 238000004062 sedimentation Methods 0.000 claims description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 8
- 208000012839 conversion disease Diseases 0.000 abstract description 4
- 239000013558 reference substance Substances 0.000 abstract description 3
- 238000004451 qualitative analysis Methods 0.000 abstract description 2
- 238000004445 quantitative analysis Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- -1 methyl hydrogen Chemical compound 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- NPUKDXXFDDZOKR-UHFFFAOYSA-N 3-(1-phenylethyl)-4-imidazolecarboxylic acid ethyl ester Chemical group CCOC(=O)C1=CN=CN1C(C)C1=CC=CC=C1 NPUKDXXFDDZOKR-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间T(min) | 流动相A(%) | 流动相B(%) |
0 | 10 | 90 |
40 | 30 | 70 |
60 | 50 | 50 |
61 | 10 | 90 |
70 | 10 | 90 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911151116.4A CN110922361B (zh) | 2019-11-21 | 2019-11-21 | 一种依托咪酯氧化杂质及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911151116.4A CN110922361B (zh) | 2019-11-21 | 2019-11-21 | 一种依托咪酯氧化杂质及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110922361A CN110922361A (zh) | 2020-03-27 |
CN110922361B true CN110922361B (zh) | 2021-01-08 |
Family
ID=69851484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911151116.4A Active CN110922361B (zh) | 2019-11-21 | 2019-11-21 | 一种依托咪酯氧化杂质及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110922361B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111533695B (zh) * | 2020-05-25 | 2021-01-08 | 武汉大安制药有限公司 | 一种依托咪酯的制备方法 |
CN114105811A (zh) * | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种新的依托咪酯杂质及制备方法和其应用 |
CN116265442A (zh) * | 2021-12-16 | 2023-06-20 | 燃点(南京)生物医药科技有限公司 | 一种依托咪酯的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101374516A (zh) * | 2006-01-27 | 2009-02-25 | 弗·哈夫曼-拉罗切有限公司 | 取代的咪唑啉的2-咪唑衍生物的用途 |
CN102046607A (zh) * | 2008-03-31 | 2011-05-04 | 通用医疗公司 | 具有提高的药物动力学性能和药效学性能的依托咪酯类似物 |
CN103588757A (zh) * | 2013-01-04 | 2014-02-19 | 四川大学华西医院 | 超短效麻醉效应的n-取代咪唑羧酸酯类化合物、制备方法和用途 |
CN103739553A (zh) * | 2013-12-23 | 2014-04-23 | 四川大学华西医院 | 含有醚侧链的n-取代咪唑羧酸酯手性化合物、制备方法和用途 |
CN104569264A (zh) * | 2014-12-30 | 2015-04-29 | 李宏 | 一种依托咪酯有关物质的测定方法 |
CN109748876A (zh) * | 2017-11-02 | 2019-05-14 | 北京蓝丹医药科技有限公司 | 依托咪酯衍生物及其制备方法 |
-
2019
- 2019-11-21 CN CN201911151116.4A patent/CN110922361B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101374516A (zh) * | 2006-01-27 | 2009-02-25 | 弗·哈夫曼-拉罗切有限公司 | 取代的咪唑啉的2-咪唑衍生物的用途 |
CN102046607A (zh) * | 2008-03-31 | 2011-05-04 | 通用医疗公司 | 具有提高的药物动力学性能和药效学性能的依托咪酯类似物 |
CN103588757A (zh) * | 2013-01-04 | 2014-02-19 | 四川大学华西医院 | 超短效麻醉效应的n-取代咪唑羧酸酯类化合物、制备方法和用途 |
CN103739553A (zh) * | 2013-12-23 | 2014-04-23 | 四川大学华西医院 | 含有醚侧链的n-取代咪唑羧酸酯手性化合物、制备方法和用途 |
CN104569264A (zh) * | 2014-12-30 | 2015-04-29 | 李宏 | 一种依托咪酯有关物质的测定方法 |
CN109748876A (zh) * | 2017-11-02 | 2019-05-14 | 北京蓝丹医药科技有限公司 | 依托咪酯衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110922361A (zh) | 2020-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110922361B (zh) | 一种依托咪酯氧化杂质及其制备方法 | |
Citti et al. | Origin of Δ9-tetrahydrocannabinol impurity in synthetic cannabidiol | |
CN110478313A (zh) | 一种卡络磺钠注射液 | |
CN109507342A (zh) | 一种测定血液样品中硝基咪唑类药物残留的方法 | |
CN109239253B (zh) | 一种阿巴卡韦的杂质的高效液相检测方法 | |
CN111983091A (zh) | 一种复方利多卡因乳膏中丙胺卡因氧化杂质的分离纯化方法 | |
CN105254612A (zh) | 一种硫辛酸杂质及其制备方法和应用 | |
CN115656398A (zh) | 一种4-氯-3-羟基丁腈的检测方法 | |
JP3575663B2 (ja) | 自動分析装置 | |
CN106770726B (zh) | 一种甲钴胺残留有机溶剂的检测方法 | |
CN105294786B (zh) | 克林霉素亚砜的合成方法 | |
CN112213407B (zh) | 一种左奥硝唑有关物质的检测方法 | |
Derdau et al. | Synthesis and analysis of isotopically stable labeled nitrosamines as mass spectrometry standards for drug impurity quality control | |
CN110208430B (zh) | 一种药物中残留环氧氯丙烷的检测方法 | |
CN112798702A (zh) | 盐酸右美托咪定原料或制剂中有关物质的检测方法 | |
CN109265496A (zh) | 一种氨基糖苷类化合物的合成方法 | |
CN104931325B (zh) | 内分泌干扰物的提取方法 | |
CN104146981B (zh) | 一种硫辛酸组合物及其制备方法 | |
US20240182435A1 (en) | Chemical synthesis method of prodelphinidin b9 gallate | |
CN114354788B (zh) | 一种Molnupiravir原料及其制剂中有关物质的测定方法 | |
Arrowood et al. | Monitoring of benzylpenicillin decomposition in gastric contents by capillary zone electrophoresis | |
CN112250657B (zh) | 一种双环醇二聚体、其制备方法及其用途 | |
CN117304029B (zh) | 4,16-[2.2]环仿苯基双酯和4-[2.2]环仿苯基单酯,其一锅合成制备方法及应用 | |
CN115819267A (zh) | 一种依托咪酯中间产物及其制备方法与应用 | |
CN111909159A (zh) | 一种依匹哌唑有关物质及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430000 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Life Science (Wuhan) Co.,Ltd. Address before: 430040 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee before: WUHAN DOCAN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430000 No.1 Xiaoxiang West Road, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Medical Nutrition Science (Wuhan) Co.,Ltd. Country or region after: China Address before: 430000 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee before: Yuanda Life Science (Wuhan) Co.,Ltd. Country or region before: China |